PANW vs PFE: Which Is the Better Buy?
Side-by-side comparison of Palo Alto Networks, Inc. and Pfizer Inc. — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-09-26.
Palo Alto Networks, Inc. · Technology
$374.74
-5.2% upside to fair value
Med Conviction
Grade C
High Quality
VS
Pfizer Inc. · Healthcare
$27.64
+12.0% upside to fair value
Med Conviction
Grade B
QuantHub Verdict
PFE has more upside to fair value
(+12.0%).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
PANW |
PFE |
| Current Price |
$374.74 |
$27.64 |
| Fair Value Estimate |
$355.11 |
$30.94 |
| Upside to Fair Value |
-5.2%
|
+12.0%
|
| Market Cap |
$305.4B |
$157.5B |
| Forward P/E |
—
|
—
|
| EV / EBITDA |
569.8x
|
17.4x
|
| Price / Sales |
26.6x
|
2.5x
|
| Price / FCF |
64.0x
|
14.3x
|
| Revenue Growth YoY |
+34.4%
|
+2.6%
|
| Gross Margin |
70.4%
|
71.3%
|
| Operating Margin |
6.1%
|
25.1%
|
| Return on Equity |
1.7%
|
4.9%
|
| Dividend Yield |
0% |
6.22% |
| FCF Yield |
1.56%
|
6.97%
|
| Analyst Consensus |
Strong Buy
|
Hold
|
Investment Thesis
Palo Alto Networks is a global cybersecurity leader built around next-generation firewalls, the Panorama management platform, and a broad subscription portfolio spanning threat prevention, cloud security, secure access, and security analytics, sold to medium and large enterprises, service providers, and governments through direct and channel distribution. The business quality is genuinely high on…
Pfizer is a global biopharmaceutical leader with a portfolio spanning cardiovascular, oncology, vaccines, immunology, and rare disease, anchored by Eliquis, the Prevnar family, Vyndaqel, Ibrance, Xtandi, Comirnaty, and Paxlovid, and supported by roughly 75,000 employees and a contract manufacturing division. Business quality is medium rather than high: TTM gross margin of 71.3% and TTM operating …
Accumulation Zones
| Metric |
PANW |
PFE |
| Zone Low |
$266.33 |
$23.21 |
| Zone High |
$301.84 |
$26.30 |
| In Buy Zone? |
No
|
No
|